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Abstract
Objective—The aim of this study was to
investigate the relation between the poly-
morphism of large molecular weight pro-
teasome (LMP) (LMP2-LMP7) and
transporter associated with antigen
processing (TAP) (TAP1-TAP2) genes and
rheumatoid arthritis (RA).
Methods—Sixty RA patients and 102 eth-
nically matched unrelated healthy sub-
jects were typed for LMP,TAP, and disease
associated HLA-DRB1 alleles by using a
new strategy based on polymerase chain
reaction-restriction fragment length poly-
morphism (PCR-RFLP) with amplifica-
tion created restriction sites.
Results—The polymorphism of LMP
(LMP2-LMP7) and TAP (TAP1-TAP2)
genes was examined in shared epitope
positive and negative RA patients and
controls. No significant diVerences in the
LMP or TAP allele frequencies were
observed between the total patient and
control groups or the patients and con-
trols positive or negative for the shared
epitope.
Conclusion—The data suggest that the
polymorphisms of LMP and TAP genes do
not have an important influence in the
pathogenesis of RA, although larger stud-
ies will be needed to provide more conclu-
sive evidence on the role of these genes in
RA. A new, highly reliable strategy for
typing LMP alleles is also described.
(Ann Rheum Dis 1998;57:33–37)
Rheumatoid arthritis (RA) is a human leuco-
cyte antigen (HLA) class II associated disease
and HLA-DR alleles that are associated with
RA across a variety of ethnic groups share a
common sequence of amino acids (residues 70
to 74) in the third hypervariable region of the
HLA-DRâ1 chain. This motif or epitope
encoded by these alleles would determine RA
susceptibility according to the “shared epitope
hypothesis”.1 However, numerous data have
evolved to indicate that the association between
the shared epitope and RA is incomplete and
that susceptibility and outcome of RA might be
controlled by multiple genes.2 3
Recent studies have identified a cluster of
genes within the class II MHC region, which
play an important part in the class I restricted
antigen presentation pathway.4–7 Two such
genes, large molecular weight proteasome
(LMP) LMP2 and LMP7 encode two protea-
some subunits, and are believed to be involved
in the degradation of cytosolic proteins and
generation of antigenic peptides. Two other
genes in this region, transporter associated with
antigen processing (TAP) TAP1 and TAP2,
encoded subunits of a transporter that translo-
cates peptides generated in the cytosol across
the endoplasmic reticulum before the assembly
of class I molecule.
The location of the genes encoding the
LMPs and TAPs within the major histocom-
patibility complex (MHC), their polymorphic
nature and their gamma interferon inducible
expression are properties shared by most com-
ponents involved in antigen presentation and
were taken as evidence implicating LMPs and
TAPs in antigen processing.8 There are some
descriptions of antigen presentation by class II
molecules utilising the endogenous presenta-
tion pathway followed by class I molecules.9
Additional data demonstrating defective class I
expression on lymphoid cells in a number of
autoimmune disease including class II associ-
ated diseases such as RA,10 support the
hypothesis that the LMP and TAP proteins
may play a part in class II restricted antigen
presentation of disease relevant peptides de-
rived from endogenous proteins. It is possible
that individual variability (polymorphism) in
structure or expression of these genes will
aVect its specificity, resulting in diVerent sets of
peptides derived from the same antigen being
presented to T cells in diVerent people. As
LMP and TAP proteins are strongly related
with the immune response to virus infection11
and there is evidence suggesting a role of virus
in the pathogenesis of RA,12 they could be
modulating susceptibility to or severity of RA,
or both. LMP and TAP genes are therefore
attractive candidates as additional RA
susceptibility/severity factors.
Methods
SUBJECTS
Sixty patients with RA and 102 ethnically
matched control individuals, who had been
previously defined for HLA-DR disease associ-
ated alleles (-DR1,-DR4, and -DR10), were
included in this study.13 Clinical and laboratory
characteristics of these patients have been
described in a previous publication13; they
included: age at disease onset, mean disease
duration, presence of rheumatoid nodules,
presence of additional extra-articular manifes-
tations, which included vasculitis and lung dis-
ease, and rheumatoid factor seropositivity.
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LMP2 AND LMP7 GENOTYPING DESIGN
The bi-allelic polymorphism at codon 60 (Arg-
His) in the LMP2 gene was analysed by
polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method
using as primers LMP2X (forward) and
LMP2Y (reverse), which amplify a 228 bp
fragment. The variant 60-Arg was typed for the
presence of a restriction site for CfoI, as
described previously.14 The variant 60-His can
be detected by the location of a restriction site
for Alw21I. However, at eight bases 3' to this
position we found a second recognition site for
Alw21I, which is present in both alleles; there-
fore it could not be used for 60-His typing. To
avoid this problem a modified primer was
designed (LMP2Y), which destroys the shared
Alw21I site, leaving intact the polymorphic site
60-Hist (fig 1A).
A recently described polymorphism at codon
145 (Lys-Gln) of the second exon in the LMP7
gene14 was also analysed by PCR-RFLP. A
fragment of 193 bp, that contains the LMP7
polymorphic site, was amplified using as prim-
ers LMP7X (forward) and LMP7Y (reverse).
Variant 145-Gln lies in a restriction site for
BsmI. To analyse the variant 145-Lys, a modi-
fied primer (LMP7Y), was designed to create a
restriction site for HindIII (fig 1B).
Genomic DNA was extracted from whole
blood using a standard phenol/chloroform
extraction before proteinase K digestion. DNA
was amplified in 50 µl reaction mixtures
containing 0.2–0.5 µg of genomic DNA using
two units of thermostable DNA polymerase
(DyNAZyme II) in the supplied 1 × reaction
buVer. Cycling conditions were as follows:
94ºC for five minutes; 30 cycles of 94ºC for one
minute, 57ºC of annealing temperature for 50
seconds in LMP2 amplifications and 62ºC for
45 seconds in LMP7, 72ºC for one minute;
72ºC for 10 minutes. The amplified fragments
were digested with the discriminating restric-
tion enzymes for two to four hours. Cleavage of
amplified fragments was detected by electro-
phoresis in 4% agarose gel (3% Nusieve, 1%
Seakem. FMC, Rockland, ME, USA.)
HLA-DR4 AND -DR1 SUBTYPING, TAP1 AND TAP2
GENOTYPING
DRB1*04 and DRB*01 subtyping was per-
formed by the “allele walking” strategy.15 Typ-
ing for TAP alleles was performed using a
method based on PCR-RFLP with amplifica-
tion created restriction sites.16
STATISTICAL ANALYSIS
The significance level (p) was obtained by
using the ÷2 test or by Fisher’s exact test, when
appropriate. The p value was corrected (pc) by
use of the Bonferoni inequality method.
Results
The patients and controls were stratified in
relation to positivity or negativity to shared
epitope to minimise the possible linkage
disequilibria between DRB1 and LMP or TAP
Figure 1 PCR-RFLP and amplification created restriction sites strategy for LMP2 (A) and LMP7 (B) typing. The
position of the polymorphic base, localisation of the nucleotide mismatch in the oligonucleotide sequence and enzyme
restriction site are indicated in boxes. Oligonucleotide sequences were as follows: LMP2X - 5'
CTTGAACCAGGGAGGCGAAGTTTG 3', LMP2Y - 5' CAGCTG AACCAGAGAGTGCATAGT 3'; LMP7X - 5'
CGGACAGATCTCTGGGTGCT 3'; LMP7Y - 5'CTTCCCTACTGCCCCAAGCT 3'. (A) CfoI digestion generated a
fragment of 199 bp for LMP2-R allele while its homologue LMP2-H was undigested resulting in a 228 bp band. LMP2-H
allele yielded a 199 bp fragment after Alw21I digestion while LMP2-R remain undigested. (B) BsmI and HindIII
generated a 179 bp fragment for alleles LMP7-Q and LMP7-K, respectively. The 193 bp band represents the undigested
product. Examples of each one of the three possible genotypes obtained in RA patients are shown. (A) LMP2 typing: #81,
LMP2-R/R; #34, LMP2-H/H; #79, LMP2-R/H. (B) LMP7 typing: #26, LMP7-Q/Q; #15, LMP7-K/K; #63,
LMP7-Q/K.Molecular weight marker (MWM): pUC19/MspI.
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genes. The DRB1 alleles carrying the shared
epitope found in our population were as
follows: DRB1*0401, 0404, 0405, 0408, 0101,
0102 and 1001.
Table 1 shows the distribution of LMP2 and
LMP7 genotype frequencies among RA pa-
tients and controls. No statistically significant
diVerences appeared between the total patient
and control groups. The increased frequency of
the LMP7-Q/K genotype observed between
patients and controls lacked statistical signifi-
cance. Moreover, the frequency of the LMP2
and LMP7 genotypes was analysed in the sub-
groups of shared epitope positive or negative
patients and controls. Increased frequencies of
the LMP2-R/R and LMP7-Q/K genotypes
were observed in the patients negative for the
shared epitope compared with the shared
epitope matched healthy controls, although the
diVerences did not reach statistical signifi-
cance.
Table 2 summarises the distribution of TAP
genotype frequencies in RA patients and
controls. As in other typing methods, the
assignment of TAP1 and TAP2 genotypes in
some heterozygotes was not possible because
each dimorphic residue is analysed individu-
ally. No statistically significant diVerences were
observed in the comparison of TAP1 and
TAP2 genotype distribution between the pa-
tients with RA and the healthy controls. Again,
no significant diVerences in the TAP1 and
TAP2 genotype frequencies were observed
between the patients positive or negative for the
shared epitope and shared epitope matched
healthy controls.
Discussion
In this study we describe a new strategy, based
on PCR double RFLP with amplification
created restriction sites, for LMP2 and LMP7
typing. This strategy, along with the previously
designed one to type TAP alleles,16 was applied
to identify LMP and TAP genotypes in our
population. We found PCR-RFLP with ampli-
cation created restriction sites a favourable
alternative to the several methods previously
used to identify LMP and TAP
polymorphisms.14–18 The most used typing
methods, PCR-SSO and PRC-SSP depend on
the diVerential hybridisation of short stretches
of DNA, therefore the possibility of false posi-
tive or negative is possible when the conditions
are not carefully adjusted. The strategy we
designed has several advantages: restriction
analysis is a potent tool to detect polymor-
phism, making false positive results very
unlikely. Only positive results are taken into
account to assign an allele, this is why the two
variants at each polymorphic residue are
assayed; the two results obtained must be con-
gruent within themselves, in this way false
negatives are practically avoided and the
homozygosity of the sample tested unequivo-
cally established. The use of amplification cre-
ated restriction sites makes it possible to create
or eliminate a restriction site when a natural
one is not available or informative. Conse-
quently, the results obtained for LMP and TAP
alleles allows the totally reliable assignment of
the genotypes of the samples studied. As in
other typing methods using genomic DNA, it
was not possible to assign TAP1 and TAP2
Table 1 LMP2 and LMP7 genotype frequencies in RA patients and normal controls
LMP genotypes
Patients
(n=60) n (%)
Controls
(n=102) n (%)
Positive for shared epitope Negative for shared epitope
Patients
(n=35) n (%)
Controls
(n=44) n (%)
Patients
(n=25) n (%)
Controls
(n=58) n (%)
LMP2-R/R 35 (58) 56 (55) 20 (57) 29 (66) 15 (60) 27 (46.5)
LMP2-H/H 1 (2) 3 (3) 1 (3) 0 0 3 (5.2)
LMP2-R/H 24 (40) 43 (42) 14 (40) 15 (34) 10 (40) 28 (48.3)
LMP7-Q/Q 48 (80) 91 (89) 28 (80) 36 (81.8) 20 (80) 55 (94.8)
LMP7-K/K 2 (3) 3 (3) 1 (3) 3 (6.8) 1 (4) 0
LMP7-Q/K 10 (17) 8 (8) 6 (17) 5 (11.4) 4 (16) 3 (5.2)
Table 2 TAP1 and TAP2 genotype frequencies in RA patients and normal controls
LMP genotypes
Patients
(n=60) n (%)
Controls
(n=61) n (%)
Positive for shared epitope Negative for shared epitope
Patients
(n=35) n (%)
Controls
(n=28) n (%)
Patients
(n=25) n (%)
Controls
(n=33) n (%)
TAP1*A/A 48 (80) 41 (67.2) 30 (85.7) 18 (64.5) 18 (72) 23 (70)
TAP1*A/C 3 (5) 1 (1.6) 1 (2.9) 1 (3.5) 2 (8) 0
TAP1*A/D 1 (1.7) 3 (5) 0 1 (3.5) 1 (4) 2 (6)
TAP1*B/C 1 (1.7) 0 1 (2.9) 0 0 0
TAP1*D/D 0 1 (1.6) 0 0 0 1 (3)
TAP1*F/F 0 1 (1.6) 0 1 (3.5) 0 0
TAP1 NA* 7 (11.6) 14 (23) 3 (8.5) 7 (25) 4 (16) 7 (21)
TAP2*A/A 14 (23.4) 14 (23) 5 (14.3) 5 (17.8) 9 (36) 9 (27.3)
TAP2*A/B 17 (28.4) 15 (24.6) 11 (31.4) 8 (28.5) 6 (24) 7 (21.2)
TAP2*A/C 5 (8.3) 5 (8.2) 4 (11.4) 2 (7.2) 1 (4) 3 (9)
TAP2*A/D 0 1 (1.6) 0 1 (3.6) 0 0
TAP2*A/E 1 (1.6) 2 (3.3) 1 (2.9) 1 (3.6) 0 1 (3)
TAP2*A/F 4 (6.7) 6 (9.8) 3 (8.6) 3 (10.7) 1 (4) 3 (9)
TAP2*B/B 7 (11.7) 5 (8.2) 3 (8.6) 1 (3.6) 4 (16) 4 (12.2)
TAP2*B/F 1 (1.6) 4 (6.6) 1 (2.9) 2 (7.2) 0 2 (6.1)
TAP2*C/C 1 (1.6) 2 (3.3) 1 (2.9) 0 0 2 (6.1)
TAP2*C/D 0 1 (1.6) 0 1 (3.6) 0 0
TAP2 NA* 10 (16.7) 6 (9.8) 6 (17) 4 (14.2) 4 (16) 2 (6.1)
TAP1*A, TAP1*B, TAP1*C, TAP1*D are identical to TAP1*0101, *02011, *0301 and *0401 respectively. TAP2*A, TAP2*B,
TAP2*E, TAP2*F are identical to TAP2 *0101, *0201, *0102 and *0103 respectively.
* NA = not assigned.
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alleles in people heterozygous at two or more
polymorphic sites. To circumvent this problem
we are currently analysing the possibility of
applying the allele walking strategy15 on cDNA
samples.
The location of polymorphic LMP and TAP
genes in the HLA class II region and their
function in antigen processing raises the ques-
tion of the relation between the polymorphism
of these genes and RA. It is interesting to note
that a substitution in mouse LMP2 (Arg →
His 40) is identical both in position and identity
of the substituted residues observed in human
LMP219 and that preliminary findings suggest
that this structural polymorphism may have
functional consequences.20 We have not found
any evidence of association between polymor-
phism in LMP2 and LMP7 genes and RA. In
agreement with our present result, a previous
study has failed to find an association between
LMP polymorphism and RA.14 Thus, it is
unlikely that LMP genes are significantly asso-
ciated with RA, although further studies with
larger numbers of patients are needed to
confirm this. In addition to the previous study
we have analysed our patient and control
groups in relation to positivity or negativity of
the shared epitope. Our negative findings are in
contrast with previous work describing an
association between LMP polymorphism and
other autoimmune disease.21
Although no naturally occurring mutations
in human TAP genes leading to a changed
peptide transport specificity have been de-
scribed so far, a recent study has shown that a
single point mutation generated by site di-
rected mutagenesis in TAP2 gene was suY-
cient to change the peptide transport
specificity.22 The recently described variations
in TAP1 (codon 648) and TAP2 (codon 651),
which have not been studied in relation to their
selectivity of transport,23 may have functional
significance. This is the first report concerning
an association between TAP genes, which
includes the polymorphisms at codons 333-
637-648 of TAP1 and at codons 379-565-651-
665-687 of TAP2 and RA. Our analysis of the
genetic polymorphism in the TAP genes in RA
patients and healthy controls indicates that
there was no association between TAP poly-
morphism and RA. Although several studies
have analysed the association of TAP genes
with RA, these reports have been limited to
TAP224 25 and they did not analyse the recently
described polymorphism in TAP1 (codon 648)
and TAP2 (codon 651).24–27 Our data confirm
and extend the previous reports where no pri-
mary association between TAP alleles and RA
was seen in diVerent populations.
LMP and TAP genes could be modulating
not susceptibility to RA but disease severity.
Therefore, we examined the relation of LMP
and TAP genotypes with clinical and labora-
tory parameters. Our preliminary data do not
suggest a significant association of LMP2-
LMP7 or TAP1-TAP2 genotypes with any of
these characteristics (data not shown). On the
other hand, it would be possible, as recently
proposed in AIDS,28 that combinations of HLA
and TAP alleles may be important in the course
of RA. Sample sizes must be larger than that
used in this study, to convincingly evaluate the
influence of these genes either individually or
as extended haplotypes in the pathogenesis of
RA.
In conclusion, the distribution of LMP2,
LMP7, TAP1, and TAP2 alleles was deter-
mined using a new strategy we designed, based
on PCR-RFLP and amplification created
restriction sites, on patients with RA and con-
trols. These results seem to rule out the
relevance of LMP and TAP polymorphism in
the pathogenesis of RA, although larger studies
will be needed to provide more conclusive evi-
dence on the role of these genes in RA.
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